Biosimilar and generic cancer drugs unlikely to bend cost curve in the USA

Lancet Oncol. 2017 Jan;18(1):22-23. doi: 10.1016/S1470-2045(16)30653-2.

Authors

Charles L Bennett¹, Oliver A Sartor², James O Armitage³, Hagop Kantarjian⁴

Affiliations

¹ University of South Carolina and the Hollings Cancer Center of the Medical University of South Carolina, Columbia and Charleston, SC 29208, USA. Electronic address: bennettc@sccp.sc.edu.
² Tulane University School of Medicine, New Orleans, LA, USA.
³ University of Nebraska Medical Center, Omaha, NE, USA.
⁴ MD Anderson Cancer Center and the University of Texas, Houston, TX, USA.

PMID: 28049571
DOI: 10.1016/S1470-2045(16)30653-2

No abstract available

MeSH terms

Antineoplastic Agents / economics*
Antineoplastic Agents / therapeutic use*
Biosimilar Pharmaceuticals / economics*
Biosimilar Pharmaceuticals / therapeutic use*
Cost Savings
Cost-Benefit Analysis
Drug Costs*
Drugs, Generic / economics*
Drugs, Generic / therapeutic use*
Economic Competition
Health Expenditures
Health Services Needs and Demand / economics
Humans
United States

Substances

Antineoplastic Agents
Biosimilar Pharmaceuticals
Drugs, Generic